Leading software and 3D printing service provider实现has contributed €2.5 million to a €4 million funding round in液体。总部位于比利时的昆蒂奇，fluidda是a biotechnology company specializing in personalized imaging solutions for respiratory diseases, i.e., pulmonology.
作为Intervent Wancraen的投资，Motialize的创始人兼首席执行官在医疗领域的3D打印方面有30年的经验，将加入Fluidda的董事会。
Vancraen说：“ Fluidda是该肺部特征的首批用户之一，这是一个很好的例子，说明如何通过与Mitalize在医学工程方面的Materalize专业知识合作开发新技术的新技术。”
“通过这种伙伴关系，我们可以帮助更多的患者，将3D印刷和计划的可能性带入肺科市场。”
功能性呼吸成像
Founded in 2005, Fluidda’s main goal is to develop imaging biomarkers to improve drug development and patient care. Its proprietary imaging technology, Functional Respiratory Imaging (FRI), is based on airflow monitoring and CT scans and provides enhanced visualizations of the lung airflow in patients.
FRI aims to better equip medical professionals in treating those ailing from progressive lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. According to Fluidda, such conditions have been seen to increase over the past few years.
Fluidda和物质化之间的合作伙伴关系将寻求开发医疗3D打印和规划解决方案，包括3D打印的肺部手术模型及其血管结构，以提高这些患者的护理质量。Fluidda首席执行官Jan De Backer补充说：
“We share the vision that the medical field, and particularly respiratory healthcare imaging needs to evolve towards personalized, precision medicine through a value-based healthcare approach. We are confident that advanced imaging techniques, such as our Functional Respiratory Imaging methods, can add value in this regard.”
物质和医疗部门
Though Materialise provides 3D printing solutions to a variety of industries it has particular strength in medical. Through its manufacturing service, the compnay produces3D printed implants， 也手术前指南用于计划和解剖模型。
In 2018 the Materialise Mimics software package was granted ’510(k) clearance由美国食品药品监督管理局（FDA），该分类最近于2019年续签。该公司现在也提供验证3D打印机可以进入医院。
Vote for your Medical, Dental or Healthcare Application of the Year in the2019 3D Printing Industry Awards。
订阅我们通讯并跟随我们FacebookandTwitter有关最新的增材制造更新。Visit our3D打印作业董事会以了解更多有关添加剂制造的机会。
特色图像显示了代表患者肺部呼吸道疾病的模型。通过Fluidda的照片。
